Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Long-Term Debt Repayments (2017 - 2022)

Sunshine Biopharma (SBFM) has disclosed Long-Term Debt Repayments for 7 consecutive years, with $1.9 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Long-Term Debt Repayments rose 3858.33% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2022, changed N/A, and an annual FY2022 reading of $1.9 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was $1.9 million for Q1 2022 at Sunshine Biopharma, up from -$451661.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.9 million in Q1 2022 and bottomed at -$451661.0 in Q4 2021.
  • Average Long-Term Debt Repayments over 5 years is $204889.5, with a median of $53767.0 recorded in 2019.
  • The sharpest move saw Long-Term Debt Repayments tumbled 523.7% in 2021, then skyrocketed 3858.33% in 2022.
  • Year by year, Long-Term Debt Repayments stood at $48000.0 in 2018, then crashed by 101.6% to -$767.0 in 2019, then surged by 13998.31% to $106600.0 in 2020, then crashed by 523.7% to -$451661.0 in 2021, then surged by 520.67% to $1.9 million in 2022.
  • Business Quant data shows Long-Term Debt Repayments for SBFM at $1.9 million in Q1 2022, -$451661.0 in Q4 2021, and $124309.0 in Q3 2021.